<VariationArchive VariationID="956890" VariationName="NM_000203.5(IDUA):c.784del (p.His262fs)" VariationType="Deletion" Accession="VCV000956890" Version="14" RecordType="classified" NumberOfSubmissions="5" NumberOfSubmitters="5" DateLastUpdated="2024-07-15" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="943734" VariationID="956890">
      <GeneList>
        <Gene Symbol="IDUA" FullName="alpha-L-iduronidase" GeneID="3425" HGNC_ID="HGNC:5391" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="986997" stop="1008351" display_start="986997" display_stop="1008351" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="980784" stop="998316" display_start="980784" display_stop="998316" Strand="+" />
          </Location>
          <OMIM>252800</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000203.5(IDUA):c.784del (p.His262fs)</Name>
      <CanonicalSPDI>NC_000004.12:1001871:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4p16.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="1001872" stop="1001872" display_start="1001872" display_stop="1001872" variantLength="1" positionVCF="1001871" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="995660" stop="995660" display_start="995660" display_stop="995660" variantLength="1" positionVCF="995659" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>p.His262ThrfsTer5</Name>
      </OtherNameList>
      <ProteinChange>H262fs</ProteinChange>
      <ProteinChange>H130fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.995661del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.995661del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.1001873del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.1001873del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008103.1" sequenceAccession="NG_008103" sequenceVersion="1" change="g.19877del">
            <Expression>NG_008103.1:g.19877del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000203.5" sequenceAccession="NM_000203" sequenceVersion="5" change="c.784del" MANESelect="true">
            <Expression>NM_000203.5:c.784del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000194.2" sequenceAccession="NP_000194" sequenceVersion="2" change="p.His262fs">
            <Expression>NP_000194.2:p.His262fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363576.1" sequenceAccession="NM_001363576" sequenceVersion="1" change="c.388del">
            <Expression>NM_001363576.1:c.388del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350505.1" sequenceAccession="NP_001350505" sequenceVersion="1" change="p.His130fs">
            <Expression>NP_001350505.1:p.His130fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_110313.1" sequenceAccession="NR_110313" sequenceVersion="1" change="n.872del">
            <Expression>NR_110313.1:n.872del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277" sequenceAccession="LRG_1277">
            <Expression>LRG_1277:g.19877del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277t1" sequenceAccession="LRG_1277t1">
            <Expression>LRG_1277t1:c.784del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1277p1" sequenceAccession="LRG_1277p1" change="p.His262fs">
            <Expression>LRG_1277p1:p.His262fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="757928590" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="protein truncation">
        <XRef ID="0015" DB="Variation Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000203.5(IDUA):c.784del (p.His262fs) AND Mucopolysaccharidosis type 1" Accession="RCV001229775" Version="7">
        <ClassifiedConditionList TraitSetID="22506">
          <ClassifiedCondition DB="MedGen" ID="C0023786">Mucopolysaccharidosis type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-06" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.784del (p.His262fs) AND Hurler syndrome" Accession="RCV001726458" Version="1">
        <ClassifiedConditionList TraitSetID="3230">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-09-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.784del (p.His262fs) AND multiple conditions" Accession="RCV002480753" Version="1">
        <ClassifiedConditionList TraitSetID="10337">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086431">Mucopolysaccharidosis, MPS-I-H/S</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0026708">Mucopolysaccharidosis, MPS-I-S</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.784del (p.His262fs) AND not provided" Accession="RCV003142193" Version="3">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-07-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-06" NumberOfSubmissions="5" NumberOfSubmitters="5" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11735025</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21480867</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27146977</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3230" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="22506" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7856" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler-Scheie syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie syndrome (former subtype; formerly known as Mucopoly-saccharidosis type V)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-L-Iduronidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDUA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis type 1</ElementValue>
                <XRef ID="MONDO:0001586" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10335" />
                <XRef ID="10335" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="579" DB="Orphanet" />
              <XRef ID="C0023786" DB="MedGen" />
              <XRef ID="MONDO:0001586" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10337" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3695" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-I-S</ElementValue>
                <XRef ID="Mucopolysaccharidosis%2C+MPS-I-S/8912" DB="Genetic Alliance" />
                <XRef ID="73123008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IS</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS V</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE V</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-S</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS5</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12561" />
                <XRef ID="12561" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93474" DB="Orphanet" />
              <XRef ID="C0026708" DB="MedGen" />
              <XRef ID="MONDO:0011760" DB="MONDO" />
              <XRef Type="MIM" ID="607016" DB="OMIM" />
            </Trait>
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
            <Trait ID="5272" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-I-H/S</ElementValue>
                <XRef ID="Mucopolysaccharidosis%2C+MPS-I-H-S/8911" DB="Genetic Alliance" />
                <XRef ID="26745009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH/S</ElementValue>
                <XRef Type="MIM" ID="607015" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-HS</ElementValue>
                <XRef Type="MIM" ID="607015" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12560" />
                <XRef ID="12560" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93476" DB="Orphanet" />
              <XRef ID="C0086431" DB="MedGen" />
              <XRef ID="MONDO:0011759" DB="MONDO" />
              <XRef Type="MIM" ID="607015" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3851004" SubmissionDate="2021-10-02" DateLastUpdated="2021-10-08" DateCreated="2021-10-08">
        <ClinVarSubmissionID localKey="SUB10450411" submittedAssembly="GRCh37" title="SUB10450411" />
        <ClinVarAccession Accession="SCV001960900" DateUpdated="2021-10-08" DateCreated="2021-10-08" Type="SCV" Version="1" SubmitterName="Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics" OrgID="505565" OrganizationCategory="other" OrgAbbreviation="FRIGE - IHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>A homozygous frameshift variation in exon 6 of the IDUA gene that results in a frameshift and premature truncation of the protein 5 amino acids downstream of Histidine to codan 262 was detected. The observed variant c.784del(p.His262ThrfsTer5) has not been reported in the 1000 genomes and has a minor allele frequency of 0.0015% in the gnomAD databases. The in silico prediction of the variant is disease causing by MutationTaster2. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as a pathogenic variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Hindu</Ethnicity>
              <GeographicOrigin>India</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina sequencing platform</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>DNA extracted from blood was used to perform targeted gene capture using a custom smMIP panel. The libraries were sequenced to mean &gt;100-300X coverage on the Illumina MiSeq sequencing platform. The sequences obtained are aligned to the human reference genome (GRCh37) using the BWA program and analyzed using Picard and GATK version 4.1.2 to identify variants relevant to the clinical indication.</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2021-09-04" Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0004322" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0000280" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0005280" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0000505" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0002650" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0002376" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0008155" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA">
              <Name>alpha-L-iduronidase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000203.5:exon 6</GeneLocation>
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">B-9215</Name>
            <Name>p.His262ThrfsTer5</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="rs757928590" />
          </XRefList>
          <FunctionalConsequence Value="protein truncation">
            <XRef DB="Variation Ontology" ID="0015" URL="http://purl.obolibrary.org/obo/VariO_0015" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.784del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10450411</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4075728" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000203.5:c.784del|Mucopolysaccharidosis type I" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002075311" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-24">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.784del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Mucopolysaccharidosis type I</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5451977" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000203.5:c.784del|OMIM:607014;607015;607016" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002801000" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.784del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607015" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607016" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7129092" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="0b6b60c755cc020dd0f29ba5e2544ffb6eb2e8f8244b36b7baf8b99f455d9c1b|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003818255" DateUpdated="2024-02-04" DateCreated="2023-03-04" Type="SCV" Version="2" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-07-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.784del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12922107</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2737230" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="4848686|MedGen:C0023786" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001402231" DateUpdated="2024-02-14" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11735025</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21480867</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27146977</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.His262Thrfs*55) in the IDUA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IDUA are known to be pathogenic (PMID: 11735025, 21480867). This variant is present in population databases (rs757928590, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with mucopolysaccharidosis type I (PMID: 27146977). ClinVar contains an entry for this variant (Variation ID: 956890). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.995660del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023786" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7129092" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0008155" MappingRef="HP">
        <MedGen CUI="C4024726" Name="Mucopolysacchariduria" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5451977" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0005280" MappingRef="HP">
        <MedGen CUI="C1836542" Name="Depressed nasal bridge" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0004322" MappingRef="HP">
        <MedGen CUI="C0349588" Name="Short stature" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002376" MappingRef="HP">
        <MedGen CUI="C1836830" Name="Developmental regression" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000505" MappingRef="HP">
        <MedGen CUI="C3665347" Name="Visual impairment" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2737230" TraitType="Disease" MappingType="XRef" MappingValue="C0023786" MappingRef="MedGen">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5451977" TraitType="Disease" MappingType="XRef" MappingValue="607015" MappingRef="OMIM">
        <MedGen CUI="C0086431" Name="Mucopolysaccharidosis, MPS-I-H/S" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4075728" TraitType="Disease" MappingType="Name" MappingValue="Mucopolysaccharidosis type I" MappingRef="Preferred">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002650" MappingRef="HP">
        <MedGen CUI="C0036439" Name="Scoliosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5451977" TraitType="Disease" MappingType="XRef" MappingValue="607016" MappingRef="OMIM">
        <MedGen CUI="C0026708" Name="Mucopolysaccharidosis, MPS-I-S" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3851004" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000280" MappingRef="HP">
        <MedGen CUI="C1845847" Name="Coarse facial features" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

